Apotex also executed a DPA with the DOJ’s Antitrust Division.
The Criminal Information against Taro Pharmaceuticals USA, Sandoz, and Apotex were filed in the United States District Court for the Eastern District of Pennsylvania. The settlement agreements do not mean the generic drugs manufacturers admitted liability nor the U.S. government conceded that its allegations are not well-founded.
In a statement, the DOJ Civil Division’s Acting Assistant Attorney general Brian Boynton said, “Illegal collaboration on the price or supply of drugs increases costs both to federal health care programs and beneficiaries. The department will use every tool at its disposal to prevent such conduct and to protect these taxpayer-funded programs.”
On the other hand, Acting U.S. Attorney for the Eastern District of Pennsylvania Jennifer Arbittier Williams said, “These civil settlements are another achievement in my office’s efforts to hold generic drug companies accountable for the consequences arising from price-fixing schemes, including the harm to federal health care programs. We will continue to aggressively pursue these violations of the Anti-Kickback Statute and the False Claims Act and obtain significant recoveries.”
